SCHEMBL1852561

SCHEMBL1852561

CCOC(=O)c1cc(-c2cccc3cc(Cc4cc(F)cc(Cl)c4)sc23)ccc1F

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR52 Q9Y2T5 5/20 0.60
HSD17B10 Q99714 3/20 0.37
S1PR5 Q9H228 7/20 0.36
S1PR4 O95977 7/20 0.36
MAPT P10636 3/20 0.36
RAB9A P51151 3/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
ALDH1A1 P00352 2/20 0.36
GAA P10253 2/20 0.36
ALOX15 P16050 2/20 0.36
NPC1 O15118 2/20 0.36
HPGD P15428 1/20 0.36
MEN1 O00255 1/20 0.36
LMNA P02545 1/20 0.36
KMT2A Q03164 1/20 0.36
PDE3B Q13370 1/20 0.36
PDE3A Q14432 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.35
KDM4E B2RXH2 1/20 0.35
TRPM8 Q7Z2W7 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1855748 0.97 GPR52 (0.57) GPR52HSD17B10S1PR5S1PR4MAPT
SCHEMBL1850522 0.88 GPR52 (0.70) GPR52S1PR5S1PR4MAPTRAB9A
SCHEMBL1859640 0.87 GPR52 (0.47) GPR52HSD17B10MAPTRAB9ASMN1; SMN2
SCHEMBL1847970 0.87 GPR52 (0.60) GPR52S1PR5S1PR4
SCHEMBL3219607 0.86 GPR52 (0.63) GPR52HSD17B10S1PR5S1PR4MAPT
SCHEMBL1850183 0.86 GPR52 (0.59) GPR52S1PR5S1PR4
SCHEMBL1854613 0.85 GPR52 (0.56) GPR52HSD17B10MAPTRAB9ASMN1; SMN2
SCHEMBL1851998 0.84 GPR52 (0.65) GPR52S1PR5S1PR4MAPTRAB9A
SCHEMBL1850515 0.83 GPR52 (0.59) GPR52HSD17B10MAPTRAB9ASMN1; SMN2
SCHEMBL1857605 0.83 GPR52 (0.59) GPR52S1PR5S1PR4MAPTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2323978-A1 AMIDE COMPOUND Takeda Pharmaceutical Company Limited (JP) 2011-05-25 EP disclosed
WO-2010018874-A1 AMIDE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-02-18 WO disclosed
US-20100041891-A1 AMIDE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-02-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100041891-A1 AMIDE COMPOUND GPR52, GPR132, NR5A2 GPR52 1/4885HSD17B10 1574/4885S1PR5 696/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.